Allogeneic osteoblastic cell therapy - Bone Therapeutics

Drug Profile

Allogeneic osteoblastic cell therapy - Bone Therapeutics

Alternative Names: ALLOB; ALLOB implantation

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bone Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta; Osteonecrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fracture; Intervertebral disc degeneration

Most Recent Events

  • 19 Feb 2018 Bone Therapeutics completes enrolment in its phase IIa trial for Intervertebral disc degeneration in Belgium
  • 23 Jan 2018 Bone Therapeutics plans a phase IIb trial for Fracture treatment in the second half of 2018
  • 20 Sep 2017 Bone Therapeutics completes the phase II ALLOB-MF1 trial in Fracture treatment in Belgium and Germany (Intraosseous) (EudraCT2015-000650-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top